FY2025 EPS Estimates for RCUS Boosted by Cantor Fitzgerald

Arcus Biosciences, Inc. (NYSE:RCUS) – Stock analysts at Cantor Fitzgerald boosted their FY2025 earnings per share estimates for shares of Arcus Biosciences in a research note issued to investors on Wednesday, October 29th. Cantor Fitzgerald analyst L. Watsek now expects that the company will post earnings per share of ($3.48) for the year, up from their prior forecast of ($3.69). The consensus estimate for Arcus Biosciences’ current full-year earnings is ($3.15) per share. Cantor Fitzgerald also issued estimates for Arcus Biosciences’ FY2026 earnings at ($4.13) EPS.

Arcus Biosciences (NYSE:RCUS) last released its quarterly earnings data on Tuesday, October 28th. The company reported ($1.27) EPS for the quarter, topping analysts’ consensus estimates of ($1.33) by $0.06. The company had revenue of $26.00 million for the quarter, compared to the consensus estimate of $19.89 million. Arcus Biosciences had a negative return on equity of 68.17% and a negative net margin of 136.40%.The company’s quarterly revenue was down 45.8% compared to the same quarter last year. During the same period last year, the business posted ($1.00) EPS.

A number of other equities research analysts have also issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcus Biosciences in a research note on Wednesday, October 8th. The Goldman Sachs Group increased their target price on Arcus Biosciences from $14.00 to $16.00 and gave the company a “neutral” rating in a research note on Thursday. HC Wainwright increased their target price on Arcus Biosciences from $24.00 to $28.00 and gave the company a “buy” rating in a research note on Wednesday. Wells Fargo & Company increased their target price on Arcus Biosciences from $25.00 to $29.00 and gave the company an “overweight” rating in a research note on Monday, October 20th. Finally, Citigroup increased their target price on Arcus Biosciences from $54.00 to $56.00 and gave the company a “buy” rating in a research note on Wednesday. Seven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Arcus Biosciences currently has an average rating of “Moderate Buy” and an average target price of $28.44.

Arcus Biosciences Stock Performance

Arcus Biosciences stock opened at $19.70 on Friday. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.65 and a quick ratio of 4.50. Arcus Biosciences has a 12 month low of $6.50 and a 12 month high of $22.11. The company has a market cap of $2.13 billion, a price-to-earnings ratio of -5.73 and a beta of 0.77. The stock’s 50-day moving average is $13.95 and its 200-day moving average is $10.73.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Gilead Sciences Inc. grew its position in shares of Arcus Biosciences by 4.5% in the 1st quarter. Gilead Sciences Inc. now owns 31,424,760 shares of the company’s stock worth $246,684,000 after acquiring an additional 1,363,636 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Arcus Biosciences by 24.1% in the 1st quarter. Vanguard Group Inc. now owns 6,687,800 shares of the company’s stock worth $52,499,000 after acquiring an additional 1,298,584 shares in the last quarter. Woodline Partners LP grew its position in shares of Arcus Biosciences by 45.5% in the 1st quarter. Woodline Partners LP now owns 5,127,304 shares of the company’s stock worth $40,249,000 after acquiring an additional 1,603,367 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Arcus Biosciences by 14.9% in the 2nd quarter. Geode Capital Management LLC now owns 1,596,329 shares of the company’s stock worth $12,995,000 after acquiring an additional 207,097 shares in the last quarter. Finally, Sofinnova Investments Inc. grew its position in shares of Arcus Biosciences by 17.2% in the 2nd quarter. Sofinnova Investments Inc. now owns 1,216,016 shares of the company’s stock worth $9,898,000 after acquiring an additional 178,240 shares in the last quarter. Institutional investors and hedge funds own 92.89% of the company’s stock.

Insider Activity at Arcus Biosciences

In other news, CAO Alexander Azoy sold 2,831 shares of Arcus Biosciences stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $13.00, for a total value of $36,803.00. Following the completion of the transaction, the chief accounting officer owned 27,363 shares in the company, valued at approximately $355,719. This trade represents a 9.38% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Jennifer Jarrett sold 37,792 shares of Arcus Biosciences stock in a transaction that occurred on Wednesday, October 8th. The stock was sold at an average price of $15.05, for a total value of $568,769.60. Following the completion of the transaction, the chief operating officer owned 214,232 shares of the company’s stock, valued at approximately $3,224,191.60. The trade was a 15.00% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 156,561 shares of company stock worth $2,916,931 over the last quarter. Company insiders own 9.60% of the company’s stock.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.